Associated Papers
Innovative rapid screening for complex BCR-ABL1 kinase domain mutations in TKI-treated leukaemia patients.
Lan Y et al.
British Journal of Cancer, 2025
40588514 (PubMed )
Supplement: 41416_2025_3098_MOESM1_ESM.pdf
Somatic mutations and outcomes in chronic myeloid leukemia adolescent and young adults compared to children, adults, and BCR::ABL1-positive acute lymphoblastic leukemia.
Krizkova J et al.
Leukemia, 2025
40295826 (PubMed )
Supplement: 41375_2025_2609_MOESM1_ESM.pdf
Comprehensive analysis of tyrosine kinase domain mutations and imatinib resistance in chronic myeloid leukemia patients.
Dhangar S et al.
Leukemia Research, 2025
Detection of kinase domain mutations in BCR::ABL1 leukemia by ultra-deep sequencing of genomic DNA.
Sánchez R et al.
Scientific Reports, 2022
35906470 (PubMed )
Supplement: 41598_2022_17271_MOESM2_ESM.pdf
Ultra-deep sequencing mutation analysis of the BCR/ABL1 kinase domain in newly diagnosed chronic myeloid leukemia patients.
Park H et al.
Leukemia Research, 2021
Somatic Mutations in Oncogenes Are in Chronic Myeloid Leukemia Acquired De Novo via Deregulated Base-Excision Repair and Alternative Non-Homologous End Joining.
Curik N et al.
Frontiers in Oncology, 2021
Ultra-accurate Duplex Sequencing for the assessment of pretreatment ABL1 kinase domain mutations in Ph+ ALL.
Short NJ et al.
Blood Cancer Journal, 2020
The Immunogenic Potential of Recurrent Cancer Drug Resistance Mutations: An In Silico Study.
Punta M et al.
Frontiers in Immunology, 2020
33133066 (PubMed )
Supplement: Table_1.xlsx › Resistance-ABL1
Comparison of Frequency and Sensitivity of BCR-ABL1 Kinase Domain Mutations in Asian and White Patients With Imatinib-resistant Chronic-Phase Chronic Myeloid Leukemia.
Kim H et al.
Clinical Lymphoma, Myeloma & Leukemia, 2018
Contributions of MET activation to BCR-ABL1 tyrosine kinase inhibitor resistance in chronic myeloid leukemia cells.
Tsubaki M et al.
Oncotarget, 2017
28418880 (PubMed )
Supplement: oncotarget-08-38717-s001.pdf
Practical management of patients with chronic myeloid leukemia who develop tyrosine kinase inhibitor-resistant BCR-ABL1 mutations.
Ai J et al.
Therapeutic Advances in Hematology, 2014
BCR-ABL1 mutations in patients with imatinib-resistant Philadelphia chromosome-positive leukemia by use of the PCR-Invader assay.
Ono T et al.
Leukemia Research, 2011
Select a paper to view details